ClinicalTrials.gg
CompletedNCT03776552GoLowUpdated Sep 22, 2026

Effectiveness of Gradual Versus Rapid Weight Loss

An interventional study of Rapid weight loss (RWL) program and Gradual weight loss (GWL) program in Obesity, sponsored by The Hospital of Vestfold. Completed at 1 site in Norway. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by The Hospital of Vestfold · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Obesity with a site in Norway — 3 open to participants now, 13 under way, 1 of them phase 3. Obesity · Norway.

Enrollment
16th of 103
293 · median 64
Started
2019
with 6 others
No phase
86 of 116
2 open now
Registered
84th of 116
by date
Lead sponsor
3 of 116
The Hospital of Vestfold

Among the 116 studies in Obesity with a site in Norway, this one is the 16th largest by enrollment of the 103 interventional ones that give a count, is one of 7 that started in 2019, is one of 86 with no phase, and was the 84th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 116 studies in Obesity with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Obesity with a site in Norway, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the 1-year effectiveness of an initial rapid weight loss (RWL) program and a gradual weight loss (GWL) program.

Read the detailed description

A total of at least 286 participants will be randomized to either a 16-week rapid weight loss (RWL) program; [an 8-week low-energy-diet (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)], or a 16-week gradual weight loss (GWL) program (controls); [estimated total energy expenditure minus 800-1000 kcal/day]. Thereafter, all participants (both groups) will undergo a 36-week comprehensive weight maintenance program.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Willing and able to give for participation in the study

      • Living in the eastern part of Norway, mainly Oslo, Buskerud, Vestfold and Akershus
      • Understanding Norwegian language written and spoken easily
      • ≥30.0 kg/m2
      • Stable body weight (\<5 kg self-reported weight change) during the last 3 months before inclusion

Exclusion criteria

Exclusion Criteria:

    • Pregnancy and breast-feeding mothers

      • Suspected non-compliance with regards to visits and/or diet
      • Severe chronic disease (endocrine disease, heart disease, neurological disease, lung disease, disease in the gastrointestinal tract, kidney disease, rheumatism or cancer).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
293 participants (actual)

Study arms

  • Active comparator
    Rapid weight loss (RWL) program

    16-week rapid weight loss (RWL) program \[8-week LED (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)\] followed by a 36-weight loss maintenance program.

    Other: Rapid weight loss (RWL) program

  • Active comparator
    Gradual weight loss (GWL) program

    16-week GWL-program (estimated total energy expenditure minus 800-1000 kcal/day) followed by a 36-weight loss maintenance program.

    Other: Gradual weight loss (GWL) program

Interventions

  • OtherRapid weight loss (RWL) program

    16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up

  • OtherGradual weight loss (GWL) program

    16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up

06

What researchers measure

Primary outcomes

  1. Change in body weight from baseline to 12 months

    Percent total body weight loss (%TBWL) at 12 months follow-up

    Time frame: Baseline to 1-year

Secondary outcomes

  1. Changes in anthropometric measures

    Waist and hip circumference (cm)

    Time frame: 4-month and 1-year

  2. Changes in body composition 1

    Bioelectrical Impedance Analysis (BIA)

    Time frame: 4-month and 1-year

  3. Changes in body composition 2

    Dual-energy X-ray Absorptiometry (DXA) in selected participants

    Time frame: 4-month and 1-year

  4. Changes in lipids

    Total-cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides (mmol/l)

    Time frame: 4-month and 1-year

  5. Changes in blood pressure

    Systolic and diastolic blood pressure (mm/Hg)

    Time frame: 4-month and 1-year

  6. Changes in glucose parameters

    HbA1c (mmol/mol)

    Time frame: 4-month and 1-year

  7. Changes in CRP

    CRP (mg/L)

    Time frame: 4-month and 1-year

  8. Changes in Health Related Quality of Life 1

    Generic questionnaire: Short Form-36 Health Survey, SF36. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores for each of the 8 domains and summary scores for physical and mental health will be calculated

    Time frame: 4-month and 1-year

  9. Changes in Health Related Quality of Life 2

    Obesity specific questionnaire: IWQOL-lite. The IWQOL-Lite is a 31-item measure of weight-related quality of life. There are five domain scores (Physical Function, Self-Esteem, Sexual Life, Public Distress and Work) and a total score. Scores for all domains and total score range from 0-100, with lower scores indicating greater impairment.

    Time frame: 4-month and 1-year

  10. Changes in Health Related Quality of Life 3

    Weight-related Symptom Measure (WRSM). The validated obesity specific WRSM measures 20 symptoms commonly related to being overweight or obese, including foot problems, joint pain, sensitivity to cold, shortness of breath, etc. using two different sets of items. The first set assesses whether or not a patient is experiencing specific symptoms, and the second set rates the level of the distress of the symptoms with values from zero ("not at all") to six ("bothers a very great deal"). The first set creates an additive scale summing symptoms from 0-20, while the second forms a symptom distress scale ranging from 0-120.

    Time frame: 4-month and 1-year

  11. Changes in symptoms of depression and anxiety

    Hospital Anxiety and Depression Scale (HADS). The validated generic HADS measures symptoms of anxiety and depression using 14 items scored from 0-3 It is decomposed into two domains measuring depression (HADS-D) and anxiety (HADS-A), both consisting of seven items yielding a score from 0-21.

    Time frame: 4-month and 1-year

  12. Changes in eating behavior

    The Three Factor Eating Questionnaire -R 21 (TFEQ-R21) measures eating behaviour and has been validated for use in individuals with obesity and will be used in the study. It consists of 21 items comprising three domain scores; (1) uncontrolled eating; assessing the tendency to lose control over eating when feeling hungry or when exposed to external stimuli, (2) cognitive restraint; assessing the conscious restriction of food intake to control body weight or body shape, and (3) emotional eating; assessing overeating related to negative mood states. The domain scores were transformed to 0-100 scales to facilitate comparison; a higher score indicates more uncontrolled, restraint, or emotional eating.

    Time frame: 4-month and 1-year

  13. Change in weight from baseline to 4 months

    Percent total body weight loss (%TBWL) at 4 months follow-up

    Time frame: 4-month

  14. Proportions of participants with a TBWL of ≥ 5%, ≥10% and ≥15% at 52-week

    TBWL of ≥ 5%, ≥10% and ≥15% at 52-week follow-up

    Time frame: 1-year

07

Study locations

1 site
  • Vestfold Hospital Trust
    Tønsberg, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Sep 2021, 29 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 29 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 14, 2018
StartActual
Apr 11, 2019
Primary completionActual
Sep 16, 2021
CompletionActual
Sep 16, 2021
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03776552
Lead sponsor
The Hospital of Vestfold
Collaborators
Roede
Responsible party
Jøran Hjelmesæth (Professor, Head, The Hospital of Vestfold) — Principal investigator
First posted
Dec 14, 2018
Start date
Apr 11, 2019
Primary completion
Sep 16, 2021
Completion
Sep 16, 2021
Last update
Sep 22, 2026

Study contacts

Jøran Hjelmesæth, Professor
principal investigator · The Hospital of Vestfold

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion